Cropsolution has discovered and characterized novel human ACC inhibitors that are potent and specific, have favorable pharmacokinetic properties, and reduce fatty acid biosynthesis in rats.

Acetyl CoA Carboxylase (ACC) is a chemically and genetically validated target for treating obesity and Type II Diabetes.

Properties of Cropsolution’s novel ACC inhibitors:

• IC₅₀ < 10 nM against both human ACCs

• Highly specific for mammalian ACCs

• Active against both ACCs in cell-based assays

• Clean in Cell and Genetic toxicity assays

• Clean in Micronucleus assays

• Unlikely to be associated with QT prolongation (low hERG potency)

• Good oral bioavailability in rats

• Favorable and predictable pharmacokinetic properties in rats

• Reduce fatty acid biosynthesis in rats

• Improve key weight loss and insulin sensitivity biomarkers in rats in vivo

Cropsolution’s proprietary ACC inhibitors are the subject of patent application WO/2010/008521

Cropsolution seeks to partner this ACC inhibitor drug program with a pharmaceutical or biotechnology company to advance this class of compounds into clinical trials.

For licensing inquiries:

Eric Ward

Cropsolution, Inc.

P.O. Box 14069

Research Triangle Park, NC 27709 USA

eward@cropsolution.com

+1 (919) 493-7452